The results were published Saturday in the New England Journal of Medicine and presented at a medical conference in Philadelphia. In the U.S., there are about 6.6 million people like those tested in the study, experts said. “This is the population who needs the medicine the most,” said Lopez-Jimenez, who had no role in the study. He expects the new findings to change treatment guidelines and “dominate the conversation” for years to come. Francisco Lopez-Jimenez, a heart expert at the Mayo Clinic. WATCH: Patients say drugs like Ozempic help with ‘food noise.’ Here’s what that meansĮxperts have known for years that losing weight can improve heart health, but there hasn’t been a safe and effective obesity medication proven to reduce specific risks, said Dr. The new study looked to see if the same was true in those who don’t have that disease. Wegovy is a high-dose version of the diabetes treatment Ozempic, which already has been shown to reduce the risk of serious heart problems in people who have diabetes. Michael Lincoff, the study’s lead author and a heart expert at the Cleveland Clinic. “It moves from a kind of therapy that reduces body weight to a therapy that reduces cardiovascular events,” said Dr. The findings could shift perceptions that the new class of obesity drugs are cosmetic treatments and put pressure on health insurers to cover them. The research is the first to document that an obesity medication can not only pare pounds, but also safely prevent a heart attack, stroke or a heart-related death in people who already have heart disease - but not diabetes. The popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20 percent in a large, international study that experts say could change the way doctors treat certain heart patients.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |